Danaher (NYSE:DHR) Price Target Lowered to $265.00 at Citigroup

Danaher (NYSE:DHR) had its target price cut by investment analysts at Citigroup from $285.00 to $265.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the conglomerate’s stock. Citigroup’s target price would indicate a potential upside of 18.75% from the company’s current price.

DHR has been the topic of a number of other reports. Stifel Nicolaus raised their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a report on Thursday, October 31st. Wells Fargo & Company lowered their target price on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday. UBS Group reduced their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Finally, TD Cowen increased their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $278.00.

Danaher Stock Down 0.3 %

NYSE DHR traded down $0.57 on Thursday, hitting $223.16. 6,666,404 shares of the stock traded hands, compared to its average volume of 3,626,230. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock has a 50-day moving average of $235.89 and a 200 day moving average of $253.45. Danaher has a twelve month low of $221.34 and a twelve month high of $281.70. The company has a market capitalization of $161.19 billion, a P/E ratio of 42.59, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same quarter last year, the company posted $2.09 EPS. As a group, analysts expect that Danaher will post 7.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Danaher

Large investors have recently made changes to their positions in the business. Wedge Capital Management L L P NC lifted its stake in Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 38 shares during the last quarter. Meridian Financial Partners LLC increased its holdings in shares of Danaher by 4.4% in the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after buying an additional 40 shares in the last quarter. Kovack Advisors Inc. lifted its position in shares of Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after acquiring an additional 41 shares during the last quarter. Well Done LLC boosted its position in shares of Danaher by 1.2% in the 3rd quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock valued at $987,000 after purchasing an additional 42 shares during the period. Finally, Waypoint Capital Advisors LLC lifted its stake in Danaher by 0.9% during the third quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock valued at $1,257,000 after buying an additional 42 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.